Why BGPT?
logo

Immunology Claims With Sources

From immune response findings to trial results, every claim traces back to its paper.Know what the science actually supports before you trust the answer.

Press Enter ↡ to search immunology



    Explore by Goal












     Quick Explanation


    Core battle-test: Across the provided corpus, β€œNET/neutrophil programs” associate with checkpoint-immunotherapy outcomes more often as predictive correlates than as proven causative NETosis biomarkers. Evidence is strongest where (i) single-cell/multi-omics define neutrophil states and (ii) independent cohorts show discrimination, but many studies still rely on retrospective design, bulk deconvolution surrogates, or prognosis endpoints rather than direct ICI response.



     Long Explanation


    Best Evidence: NET markers & ICI outcomes β€” Evidence audit (known vs inferred vs uncertain)

    Date reference: March 23, 2026 (user-provided). All claims below are grounded only in the provided dataset snippets and their referenced DOIs/URLs via inline citations.

    Evidence map (what each source actually supports about β€œNET markers” and β€œICI outcomes”)

    Only papers present in your provided dataset are included below.
    Paper (context) NET / neutrophil signal used Outcome linked to Strength (from snippet) Key limitation relevant to NET↔ICI causality
    JCI 2025: teplizumab response in T1D
    Not classic ICI, but immune checkpoint-like therapy outcome stratification
    		 Neutrophil-enriched resistance signature; 26-gene β€œResponse Score” includes neutrophil-associated genes and contrasts with NK/CD8-T responder signature. Therapy response (remission / responders vs non-responders) across AbATE stage 3 and TN10 stage 2. AUC ~0.97; sensitivity ~93%; specificity ~98% (cross-cohort bootstrap summary in snippet). Limited external prospective validation; mouse-to-human translatability; signature stability assumptions; teplizumab β‰  PD-1/PD-L1 ICI mechanistically.
    npj Precision Oncology 2022: baseline predictors of PD-1 axis long-term benefit (melanoma)
    		 12-gene LTB signature includes CXCL8 and DEFB134 (chemokine/defensin programs that often track neutrophil activity), plus other immune genes (e.g., IDO1, MYD88). Long-term benefit at 24 months after PD-1 axis blockade. AUC 0.92 discovery; AUC 0.74 validation; external dataset AUC 0.87 reported in snippet. Retrospective design; retrospective FFPE-to-panel platform; predictive time-horizon; signature is not explicitly a β€œNET marker” but a neutrophil-associated expression program.
    BMC Cancer 2025: scRNA NDRGs predict immunotherapy response (CRC)
    		 Neutrophil differentiation–related genes; states shift with ICI; model uses elastic-net score from selected NDRGs. ICI response prediction using TIDE surrogate (snippet), plus AUC in training/validation contexts. AUC 0.78 in TCGA-COAD training context (as reported in snippet); directionality ties to TIDE scores. Retrospective/public-data dependence; TIDE is a surrogate; cohort/batch effects; not explicitly NETosis (NET structure) rather than differentiation/phenotype.
    npj Precision Oncology 2024: multiomics NETosis heterogeneity (PDAC)
    		 NETosis heterogeneity subtypes (NET_PDE4B+, NET_IL1B+, NET_TLR2+); NET signature and IL1B/TLR2 biomarkers. Prognosis (OS) and immune suppression correlates; also suggests immunotherapy relevance but snippet is prognostic-first. OS direction for TLR2 differs by cohort (snippet: in-house longer OS; ICGC shorter OS). Correlational; cohort-specific direction instability; limited in vivo mechanistic validation due to neutrophil lifespan; NET↔ICI causal chain not established in snippet.
    Journal of Translational Medicine 2025: neutrophils & PD-1/PD-L1 in NSCLC (review)
    		 NETs discussed mechanistically (e.g., MPO activity, cytokine axes) as modulators of PD-1/PD-L1 response. Therapy response/resistance (reviewed evidence across studies). Synthesis; no new numeric discrimination in snippet. Narrative review; heterogeneous models/markers; translational inconsistencies; review-level evidence cannot establish NET marker validity for ICI outcomes.

    Battle-test conclusion: what is actually β€œbest evidence” here?

    Known from provided evidence (not causality claims):
    • A neutrophil-enriched blood transcriptomic program correlates with teplizumab non-response in T1D (Response Score AUC ~0.97 across described cohorts), but this is not PD-1/PD-L1 ICI specifically, and mechanistic equivalence to NETosis is not established in the snippet.
    • In melanoma, a baseline 12-gene signature that includes CXCL8 and DEFB134 (chemokine/defensin programs often aligned with neutrophil activity) predicts long-term benefit after PD-1 axis blockade with AUC ~0.74 in validation in the snippet. This is an expression predictor, not a direct NET structural marker panel.
    • In colorectal cancer, a neutrophil differentiation–gene model predicts ICI response (snippet references TIDE surrogate and multiple cohort validation), reaching AUC ~0.78 in TCGA-COAD as reported; however, this is again a neutrophil program rather than an experimentally defined NETosis marker assay.
    • In pancreatic ductal adenocarcinoma, NETosis heterogeneity is addressed directly in a multi-omics/scRNA framework, with NET subtype marker examples including PDE4B, IL1B, TLR2, and a single-gene biomarker discussion for TLR2β€”but the snippet explicitly indicates cohort-dependent direction for OS associations (TLR2 longer OS in one cohort, shorter OS in another), which weakens β€œuniversal NET marker” claims.
    Uncertain / not proven by provided evidence:
    • That NET structural markers measured in blood/tumor causally drive ICI response rather than merely co-varying with immune suppression states. The provided NET-focused PDAC paper snippet supports prognostic associations, while ICI outcome links in the snippet are not directly numeric in a β€œNET marker β†’ ICI response” causal chain.
    • Assay equivalence: β€œNET marker” could mean (a) NETosis gene programs, (b) NET structural components (e.g., MPO-DNA, citrullinated histone H3), or (c) downstream neutrophil differentiation states. Your provided dataset snippets mostly supply (a) and (b) implicitly; ICI prediction often uses expression signatures rather than standardized NET biomarker assays.
    Most important blind spots (based strictly on the provided snippets):
    • Retrospective/heterogeneous endpoints: melanoma LTB is time-dependent retrospective prediction; CRC uses TIDE surrogate; PDAC snippet is prognosis-first rather than ICI-response-first. This makes β€œNET markers β†’ ICI outcome” comparisons indirect.
    • Cross-dataset instability: PDAC TLR2 OS direction changes across cohorts in the snippetβ€”this is a red flag for β€œsingle NET marker” generalizability.
    Confidence (overall, for β€œNET markers predict ICI outcomes” based on provided evidence):
    Moderate. Multiple studies show neutrophil-associated transcriptomic signals correlating with checkpoint-related outcomes, but the snippet set does not consistently establish that NETosis-specific markers (as directly measured NET structures) are the driver rather than a correlate. Also, some NET-related biomarkers show cohort-dependent direction.

    What would most disprove/reshape this β€œNET markers ↔ ICI outcome” idea?

    • Prospective, standardized NET marker assays (NET structural biomarkers and/or validated NETosis readouts) showing no discrimination for PD-1/PD-L1 long-term benefit across multiple independent cohorts.
    • Intervention studies that block NETosis and show no restoration of checkpoint response (i.e., no change in objective ICI response rates) even while NET marker levels fall.
    • Demonstrations that neutrophil differentiation signatures (e.g., defensin/chemokine programs) predict ICI outcomes equally well when NET-specific features are removed or orthogonalized.
    Use the agent to (1) extract all NET/TAN-related gene markers explicitly from the included snippets, (2) map them onto outcome types (OS vs LTB vs predicted ICI response), and (3) compute a consistency score across cohorts using only the provided numeric performance summaries.


    Feedback:    

    Updated: March 23, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    Computes a consistency matrix linking explicitly listed neutrophil/NET genes to outcome type (LTB/OS/surrogate response) and plots cohort/study-wise AUC/direction agreement using provided snippet metrics.



     Hypothesis Graveyard


    A single canonical NET marker (e.g., TLR2 alone) is universally predictive of ICI benefit across cancersβ€”implausible given explicit cohort-dependent OS direction for TLR2 in the PDAC NETosis snippet.


    NET marker positivity is sufficient to guarantee ICI resistance regardless of tumor typeβ€”contradicted by the mixture of prognostic vs predictive outcomes and by the signature context (melanoma LTB vs PDAC OS vs CRC surrogate response).

     Science Art


    Best Evidence: NET markers and ICI outcomes Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending